Company research
Ampio Pharmaceuticals, Inc.
CIK 1411906Updated Sep 24, 2026
SecurityAMPE · OTC · equity
Name history
Chay Enterprises, Inc. · through Mar 17, 2010
AMPE price & chart
Loading TradingView…
OTC:AMPE on TradingView ↗In the news
No coverage from other publishers is available.
Recent filings
Other Events
Items 8.01, 9.01
15-12G filing
25 filing
10-K filing
8-K filing
Show 5 more recent filings
Financials
FY 2023 · USDSource
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 5,736,000Source | 13,588,000Source | 38,825,000Source | 22,878,000Source |
| Property, Plant and Equipment, NetUSD | 0Source | 184,000Source | 2,564,000Source | 3,561,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 4,089,000Source | 12,653,000Source | 33,892,000Source | 17,346,000Source |
| Assets, CurrentUSD | 5,736,000Source | 13,329,000Source | 35,632,000Source | 18,493,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 727,000Source | 676,000Source | 1,740,000Source | 1,147,000Source |
| Operating Lease, Right-of-Use AssetUSD | 0Source | 75,000Source | 629,000Source | 824,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 2,376,000Source | 1,799,000Source | 11,541,000Source | 5,366,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 0Source | 2,000Source | 23,000Source | 19,000Source |
| Retained Earnings (Accumulated Deficit)USD | -242,527,000Source | -233,939,000Source | -217,602,000Source | -200,527,000Source |
| Stockholders' Equity Attributable to ParentUSD | 3,360,000Source | 11,789,000Source | 27,284,000Source | 17,512,000Source |
| Additional Paid in Capital, Common StockUSD | 245,887,000Source | 245,726,000Source | 244,863,000Source | 218,020,000Source |
| Liabilities and EquityUSD | 5,736,000Source | 13,588,000Source | 38,825,000Source | 22,878,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 2,376,000Source | 1,192,000Source | 5,122,000Source | 1,834,000Source |
| Operating Lease, Liability, CurrentUSD | 274,000Source | 340,000Source | 311,000Source | 284,000Source |
| Accounts Payable, CurrentUSD | 750,000Source | 97,000Source | 427,000Source | 186,000Source |
| Operating Lease, Liability, NoncurrentUSD | 0Source | 274,000Source | 614,000Source | 925,000Source |
cash flow · annual statements
| Line item | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -8,632,000Source | -16,337,000Source | -17,075,000Source | -15,894,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 122,000Source | 1,048,000Source | 1,094,000Source | 1,177,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 159,000Source | 1,462,000Source | 2,724,000Source | 1,277,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -8,564,000Source | -21,128,000Source | -14,089,000Source | -14,729,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 0Source | 0Source | -97,000Source | -63,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | 0Source | 97,000Source | 63,000Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 0Source | 79,000Source | 186,000Source | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 0Source | -111,000Source | 30,732,000Source | 25,606,000Source |
| Proceeds from (Payments for) Other Financing ActivitiesUSD | — | — | — | -2,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -8,564,000Source | -21,239,000Source | 16,546,000Source | 10,814,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 159,000Source | 953,000Source | 2,804,000Source | 1,357,000Source |
| Asset Retirement Obligation, Accretion ExpenseUSD | 5,000Source | — | — | — |
| DepreciationUSD | — | — | 1,094,000Source | 1,177,000Source |
| Gain (Loss) on Derivative Instruments, Net, PretaxUSD | 0Source | 5,761,000Source | 3,492,000Source | -543,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | -56,000Source | — | 0Source | -73,000Source |
| Gain (Loss) on Sale of Assets and Asset Impairment ChargesUSD | 289,000Source | — | — | — |
| General and Administrative ExpenseUSD | 7,079,000Source | 11,466,000Source | 8,671,000Source | 6,662,000Source |
| Net Income (Loss) Attributable to ParentUSD | -8,632,000Source | -16,337,000Source | -17,075,000Source | -15,894,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -8,632,000Source | -22,098,000Source | -20,567,000Source | -15,894,000Source |
| Nonoperating Income (Expense)USD | 942,000Source | 5,981,000Source | 3,496,000Source | -60,000Source |
| Operating ExpensesUSD | 9,574,000Source | 22,318,000Source | 20,571,000Source | 15,834,000Source |
| Operating Lease, Impairment LossUSD | 0Source | 322,000Source | — | — |
income statement · annual statements
| Line item | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|
| Net Income (Loss) Attributable to ParentUSD | -8,632,000Source | -16,337,000Source | -17,075,000Source | -15,894,000Source |
| Earnings Per Share, BasicUSD per share | -10.66Source | -1.08Source | -0.09Source | -0.09Source |
| Earnings Per Share, DilutedUSD per share | -10.66Source | -1.47Source | -0.1Source | -0.09Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 810,113Source | 15,072,308Source | 199,299,072Source | 172,846,773Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 810,113Source | 15,072,308Source | 204,963,019Source | 172,846,773Source |
| Additional Financial Items | ||||
| Gain (Loss) on Derivative Instruments, Net, PretaxUSD | 0Source | 5,761,000Source | 3,492,000Source | -543,000Source |
| General and Administrative ExpenseUSD | 7,079,000Source | 11,466,000Source | 8,671,000Source | 6,662,000Source |
| Interest Income (Expense), Nonoperating, NetUSD | 348,000Source | 220,000Source | 4,000Source | 12,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -8,632,000Source | -22,098,000Source | -20,567,000Source | -15,894,000Source |
| Nonoperating Income (Expense)USD | 942,000Source | 5,981,000Source | 3,496,000Source | -60,000Source |
| Operating ExpensesUSD | 9,574,000Source | 22,318,000Source | 20,571,000Source | 15,834,000Source |
| Research and Development ExpenseUSD | 2,439,000Source | 8,916,000Source | 11,900,000Source | 9,172,000Source |
Filing attachments
tm254694d1_ex99-1.htm · 8-K · 2025-01-29
EX-99.1 2 tm254694d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 DISTRICT COURT, CITY & COUNTY OF DENVER, STATE OF COLORADO 1437 Bannock Street Denver, Colorado 80202 COURT USE ONLY Plaintiff: JOR…
Read attachment ↗tm254694d1_ex99-2.htm · 8-K · 2025-01-29
EX-99.2 3 tm254694d1_ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 DISTRICT COURT, CITY & COUNTY OF DENVER, STATE OF COLORADO 1437 Bannock Street Denver, Colorado 80202 COURT USE ONLY Plaintiff: JORDAN LEAJAMES (MCCANN), Derivatively on Behalf of AMPIO Case Number: 2023CV30287 PHARMACEUTICALS, INC., Division: 280 v. Defenda…
Read attachment ↗